Concepedia

Author

Denise Casey

United States Food and Drug AdministrationORCID

Also Known As

D. Casey, D.E. Casey, Denise Casey

25

Publications

452

Citations

10

H-Index

28

Concepts

All Affiliations

United States Food and Drug AdministrationCenter for Drug Evaluation and ResearchMassachusetts General Hospital
DC

About

Denise Casey is an author at United States Food and Drug Administration specializing in medicine, pharmacology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

89

2

Pharmacology

3

3

89

3

Health Sciences

1

1

18

4

Public Health

1

1

36

5

Health Policy

1

1

36

Denise Casey

×

9

Publications

410

Citations

9

H-Index

YearCitations

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma

Denise Casey, Suzanne Demko, Stacy S. Shord,

Clinical Cancer Research

2017

125

FDA Approval Summary: Selumetinib for Plexiform Neurofibroma

Denise Casey, Suzanne Demko, A. K. Sinha,

Clinical Cancer Research

2021

99

Health Care Failure Mode and Effect Analysis to Reduce NICU Line–Associated Bloodstream Infections

Celeste J. Chandonnet, Prerna S. Kahlon, Pratik Rachh,

PEDIATRICS

2013

44

Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities

Amy Barone, Denise Casey, Amy E. McKee,

Pediatric Blood & Cancer

2019

36

Accelerating the Global Development of Pediatric Cancer Drugs: A Call to Coordinate the Submissions of Pediatric Investigation Plans and Pediatric Study Plans to the European Medicines Agency and US Food and Drug Administration

Gregory H. Reaman, Dominik Karres, Franca Ligas,

Journal of Clinical Oncology

2020

35

Feasibility of Early Palliative Care Consultation for Children With High-Risk Malignancies

Laila A. Mahmood, Denise Casey, James G. Dolan,

Pediatric Blood & Cancer

2016

27

Wound healing complications with lenvatinib identified in a pharmacovigilance database

Connie Cheng, Afrouz Nayernama, S. Christopher Jones,

Journal of Oncology Pharmacy Practice

2018

18

Clinical trial design for cutaneous neurofibromas

Ashley Cannon, Kurt Jarnagin, Bruce R. Korf,

Neurology

2018

15

Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.

Jason J. Luke, Manish Sharma, Sreenivasa R Chandana,

Journal of Clinical Oncology

2023

11

Page 1